Risk of recurrence and survival after relapse in patients with Ewing sarcoma
Pediatric Blood & Cancer2011Vol. 57(4), pp. 549–553
Citations Over TimeTop 10% of 2011 papers
Martin Stahl, Andreas Ranft, Michael Paulussen, Tobias Bölling, Volker Vieth, Stefan Bielack, Irene Görtitz, Gabriele Braun‐Munzinger, Jendrik Hardes, Heribert Jürgens, Uta Dirksen
Abstract
5-year OSr in Ewing sarcoma is poor (2 years) and strictly localized relapse.
Related Papers
- → Survival of Patients with Ewing's Sarcoma in Yazd-Iran(2014)5 cited
- → A comparison of the clinical characteristics of second primary and single primary sarcoma: A population based study(1992)23 cited
- → Is Treatment Response Prognostic in Non–Small-Cell Lung Cancer?(2015)
- → Cetuximab combined with chemotherapy prolonged the overall survival of advanced NSCLC(2008)
- → A Comparison of Overall Survival between Definitive Local Therapy and Systemic Therapy in Metastatic Sinonasal Malignancies(2021)